Literature DB >> 2766302

Autocrine tumor cell growth-inhibiting activities from human malignant melanoma.

U Bogdahn1, R Apfel, M Hahn, M Gerlach, C Behl, J Hoppe, R Martin.   

Abstract

Autocrine-secreted tumor cell growth-inhibiting activities were isolated from supernatants of a malignant melanoma cell line, HTZ 19-dM, established from a central nervous system melanoma metastasis. HTZ 19-dM was characterized by cyto- and immunocytochemistry and karyotyping; cells were propagated in defined serum-free tissue culture medium for up to 8 months. Supernatants were ultrafiltrated, dialyzed, lyophilized, and purified by Bio-Gel P-10 gel permeation chromatography, leading to three active fraction pools, MIAI [melanoma-inhibiting activity (MIA), 2 kDa), MIAII (Mr 11,500-17,000) and MIAIII (proteins at the cutoff of Bio-Gel P-10) inhibiting growth of 19-dM cells with 50% inhibitory concentrations of 0.79 microgram/ml (MIAI), 0.13 microgram/ml (MIAII), and 16.7 micrograms/ml (MIAII). MIAII could be further purified by reverse phase high pressure liquid chromatography; the main activity displayed a 50% inhibitory concentration of 0.33 microgram/ml. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis one major band (molecular weight about 14,000) and two minor bands (up to Mr 17,000) were identified. Macromolecular synthesis was inhibited in 19-dM cells up to greater than 99.5%; tumor stem cell colony formation was reduced by 99.89%; the inhibitory effect of MIAII was irreversible, nonsaturable, and partially antagonized by a serum factor (depending on purification stage). MIAII was heat stable (3 min at 100 degrees C) and trypsin labile. The effect of MIAII on allogeneic neuroectodermal tumors was also investigated; proliferation of two of three malignant melanomas and two of four glioblastomas was inhibited up to 85.2%; proliferation of a neuroblastoma cell line could be inhibited to 33.8%, whereas normal fibroblasts and low grade gliomas were not influenced in their proliferation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766302

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold.

Authors:  R Stoll; C Renner; M Zweckstetter; M Brüggert; D Ambrosius; S Palme; R A Engh; M Golob; I Breibach; R Buettner; W Voelter; T A Holak; A K Bosserhoff
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

2.  [Serum markers for melanoma].

Authors:  S Ugurel
Journal:  Hautarzt       Date:  2005-02       Impact factor: 0.751

3.  Growth modulation of human tumor cells by a growth-inhibiting activity derived from tumorigenic V79 Chinese hamster cells.

Authors:  I Ichinose; S Nakano; T Esaki; T Koga; K Mitsugi; H Yamada; Y Niho
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-04       Impact factor: 2.416

Review 4.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

5.  Backbone dynamics of the human MIA protein studied by (15)N NMR relaxation: implications for extended interactions of SH3 domains.

Authors:  Raphael Stoll; Christian Renner; Reinhard Buettner; Wolfgang Voelter; Anja-Katrin Bosserhoff; Tad A Holak
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

6.  Misexpression of MIA disrupts lung morphogenesis and causes neonatal death.

Authors:  Sui Lin; Machiko Ikegami; Yan Xu; Anja-Katrin Bosserhoff; Alvin M Malkinson; John M Shannon
Journal:  Dev Biol       Date:  2008-02-15       Impact factor: 3.582

Review 7.  Growth factors in melanoma.

Authors:  U Rodeck; M Herlyn
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 8.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

Review 9.  Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies.

Authors:  Jochen Utikal; Dirk Schadendorf; Selma Ugurel
Journal:  Arch Dermatol Res       Date:  2007-03       Impact factor: 3.017

Review 10.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.